a smaller reporting company, we are not required to provide disclosure pursuant to this item in this Form 10-Q.
−Removed: However, as of the date
−Removed: of this Quarterly Report, other than as set forth below, there have been no material changes with respect to those risk factors previously
−Removed: disclosed under “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as
−Removed: filed with the Securities and Exchange Commission on March 13, 2023 (the “Form 10-K”).
−Removed: The following should be carefully
−Removed: considered, together with other information in this Quarterly Report on Form 10-Q, our Form 10-K, and our other filings with the SEC
−Removed: before making investment decisions regarding our Common Stock.
+Added: However, as of the
+Added: date of this Quarterly Report, other than as set forth below, there have been no material changes with respect to those risk factors
+Added: previously disclosed under Item 1A.
+Added: Risk Factors in our Form 10-K.
+Added: following should be carefully considered, together with other information in this Quarterly Report on Form 10-Q, our Form 10-K, and
+Added: our other filings with the SEC before making investment decisions regarding our Common Stock.
results of our research and development efforts are uncertain and there can be no assurance they will enhance the commercial success
2 unchanged sentences
lamps to better fulfill the needs of dermatologists and may also incur research and development expenditures to develop new products.
−Removed: The products we are developing and may develop in the future may not be technologically successful.
−Removed: At this time, we have limited internal
−Removed: research and development personnel, which makes us dependent on consulting relationships.
−Removed: addition, the length of our product development cycle may be greater than we originally expected, and we may experience delays in product
−Removed: If our resulting products are not technologically successful, they may not achieve market acceptance or compete effectively
−Removed: with our competitors’ products and services.
−Removed: is substantial doubt about our ability to continue as a “going concern.”
−Removed: connection with our assessment of going concern considerations under applicable accounting standards, the Company’s management
−Removed: has determined that our growth plans, upcoming inventory purchases and a final settlement payment to DUSA Pharmaceuticals, Inc.
−Removed: doubt exists about our ability to continue as a going concern through approximately one year from the date the unaudited condensed financial
−Removed: statements included in Item 1.
−Removed: “Financial Statements” were issued.
−Removed: The future viability of the Company is dependent on its
−Removed: ability to continue to execute its growth plan and raise additional capital or find alternative methods of financing to fund its operations.
−Removed: There can be no guarantee that the actions presently being taken by the Company will be successful in raising additional capital or finding
−Removed: alternative methods of financing.
−Removed: If the Company is not successful in these endeavors, it would likely have a material adverse effect
−Removed: on the Company’s business, results of operations and financial condition.
−Removed: additional discussion of the risks and uncertainties that affect our business, see “Item 1A.
−Removed: Risk Factors” included in our
+Added: At this time, we have limited internal research and development personnel, which makes us dependent on consulting relationships.
+Added: products we are developing and may develop in the future may not be technologically successful.
+Added: In addition, the length of our
+Added: product development cycle may be greater than we originally expected, and we may experience delays in product development.
+Added: If our resulting
+Added: products are not technologically successful, they may not achieve market acceptance or compete effectively with our competitors’
+Added: products and services, which may materially and adversely affect our business, financial condition, results of operations and growth
Unregistered Sales of Equity Securities and Use of Proceeds.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.